Overview

Oral Androgens in Man-4: (Short Title: Oral T-4)

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Washington
Collaborator:
GlaxoSmithKline
Treatments:
Androgens
Dutasteride
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate